How Sarcopenic Obesity Quietly Drives Fatty Liver Disease Risk

The liver rarely comes up in conversations about muscle and fat. Most people associate fatty liver disease with heavy drinking or with obesity in its most visible form. But a growing body of research, including a large meta-analysis published in 2025, points to a much more specific and less obvious driver: sarcopenic obesity, the combination of low muscle mass or function with excess body fat that this site focuses on. The relationship goes both ways, and it appears to start well before old age. This post works through what the evidence actually shows, how muscle and liver tissue seem to communicate with each other, and what, if anything, can be done about it.

What Fatty Liver Disease Has to Do with Muscle

The condition once widely known as non-alcoholic fatty liver disease has been renamed metabolic dysfunction-associated steatotic liver disease, or MASLD, to better reflect its roots in metabolic dysfunction rather than in alcohol use. It is one of the most common chronic liver conditions worldwide, affecting up to roughly a quarter of the global population according to a 2024 systematic review published in the journal Sci by Martins-Mendes and colleagues. For a long time, MASLD was studied almost entirely as a liver and fat problem. A 2025 review in Nature Reviews Endocrinology by Zheng and colleagues describes a shift in that thinking, arguing that MASLD, sarcopenia, and metabolic syndrome are so closely linked that they should be assessed and treated together rather than as separate conditions. Muscle, in other words, is not a bystander in liver disease. It appears to be an active participant.

What a Large 2025 Meta-Analysis Actually Found

The clearest picture of how strong this connection is comes from a systematic review and meta-analysis published in Nutrition & Metabolism in 2025 by Wang, Liu, Du, Qiu, Liu, Xu, and Zhang. The authors pooled data from thirteen studies covering 35,373 people with sarcopenic obesity across six countries. Their headline finding was striking: 63.4 percent of people with sarcopenic obesity also had MASLD. Compared with people who did not have sarcopenic obesity, those who did were significantly more likely to have MASLD, with a pooled odds ratio of 4.45 (95 percent confidence interval: 2.57 to 7.72). The relationship was not limited to simple fat accumulation in the liver either. People with sarcopenic obesity also had more than double the risk of MASLD-related fibrosis, the more advanced stage in which the liver begins to scar, with an odds ratio of 2.34 (95 percent confidence interval: 1.78 to 3.08).

The review also looked at whether the risk differed between men and women, reporting separate odds ratios for each sex (4.22 for women and 7.56 for men). Both figures were statistically significant on their own, but their confidence intervals overlapped substantially, so this analysis cannot say with confidence that one sex is more affected than the other. What is clear is that the association between sarcopenic obesity and MASLD held up across a large, multi-country sample, even though the authors noted considerable heterogeneity between the included studies and called for more consistent diagnostic definitions going forward.

The Two Way Signaling Between Muscle and Liver

An association this strong raises an obvious question: does a fatty liver cause muscle loss, does muscle loss cause a fatty liver, or do the two drive each other? The mechanistic evidence points mostly toward the third option. This site has previously covered how fat and muscle signal each other into a vicious cycle in sarcopenic obesity; the liver turns out to be deeply woven into that same signaling network. A 2023 review in the journal Nutrients by Bouzakri and colleagues lays out how skeletal muscle communicates with the liver through secreted proteins called myokines. Some myokines, including irisin, interleukin-15, and fibroblast growth factor 21, tend to support fat oxidation and better insulin sensitivity in the liver when muscle is active and well maintained. Myostatin, a myokine that restrains muscle growth, behaves differently: elevated myostatin, more common in inactive or atrophying muscle, has been linked to worse metabolic outcomes and appears to promote hepatic fat accumulation instead of limiting it.

Put together, the pattern looks like this: less or weaker muscle tends to mean fewer of the metabolically favorable myokines and comparatively more myostatin activity, which nudges the liver toward storing more fat and becoming more insulin resistant. A liver that is already fatty and insulin resistant then contributes to systemic inflammation and disrupted glucose handling, conditions that make it harder for muscle to build and maintain protein in the first place. Rather than one organ failing and dragging the other down, the evidence suggests a genuine feedback loop, which is consistent with why sarcopenic obesity carries risks that are often greater than either low muscle mass or excess fat would predict on its own.

Why How You Measure Muscle Changes the Answer

One important nuance comes from the 2024 systematic review by Martins-Mendes and colleagues mentioned earlier. After screening over a thousand studies, the authors included 42 full papers examining the relationship between low muscle mass, strength, or performance and MASLD. Most of these studies did find an association between low muscle mass and low strength and the presence or severity of MASLD. But the association depended heavily on how muscle mass was measured: it showed up clearly when muscle mass was adjusted for body weight or BMI, but not when it was adjusted for height. The methods used to define both low muscle mass and MASLD varied so much across studies that the authors could not even perform a formal meta-analysis, and they called explicitly for standardized measurement approaches. This mirrors a point this site has made before in discussing why sarcopenic obesity diagnosis depends on which definition you use: the same person's risk can look different depending on which yardstick a study or a clinician applies.

Can Exercise Reverse It? What Controlled Trials Show

Association and mechanism are one thing; whether intervening on muscle actually changes liver outcomes in a trial is another, and here the evidence is more direct and more encouraging. A systematic review and meta-analysis published in Frontiers in Physiology in 2025 by Dai and colleagues pooled eleven randomized controlled trials, totaling 395 participants, testing resistance exercise specifically in people with MASLD. Resistance training significantly reduced alanine aminotransferase, a blood marker of liver strain, by a mean of 4.44 U/L compared with control groups. Among the eight trials that used imaging to directly measure liver fat, seven reported meaningful reductions in liver fat content with resistance training. No significant change was found in aspartate aminotransferase, and no serious adverse events were reported, with compliance similar between exercise and control groups.

Based on the pooled trial data, the authors proposed a minimum effective dose: whole-body, multi-muscle resistance training consisting of eight to ten exercises performed at 60 to 80 percent of one-repetition maximum, done at least three times per week for a minimum of twelve weeks. The authors specifically noted this may be particularly useful for people who cannot tolerate aerobic exercise due to elevated liver enzymes or other limitations. This finding lines up with this site's earlier discussion of resistance training volume and the dose response evidence for sarcopenic obesity, and adds the liver as another organ that appears to respond meaningfully to the same kind of structured strength training already recommended for muscle preservation.

Practical Implications

For a young adult, the practical message is not that fatty liver disease is only a concern for people who are visibly overweight or older. The sarcopenic obesity and MASLD link described here includes people whose weight and BMI look unremarkable, which is exactly the population this site's affiliated research project on young Omani adults is trying to better characterize. Someone who is sedentary, eats a low-protein or highly processed diet, and has never had a body composition assessment may be carrying real hepatic risk without any outward sign of it. Basic liver enzyme testing, alongside the body composition measures discussed in this site's complete guide to sarcopenic obesity in young adults, gives a more complete picture than weight alone. And unlike many risk factors, this one appears to respond to an intervention already recommended for muscle health: structured resistance training performed consistently over months, not simply weight loss through calorie restriction, which this site has separately cautioned can itself strip away muscle.

Limitations and What Remains Uncertain

Several caveats are worth stating plainly. Most of the epidemiological evidence linking sarcopenic obesity to MASLD, including the 35,373-person meta-analysis discussed above, is drawn from cross-sectional studies, which can establish association but cannot on their own prove which condition comes first in a given person. The randomized trial evidence for resistance training is more directly causal, but it is still based on a relatively small pooled sample of 395 participants across eleven trials, mostly over periods of twelve to twenty-four weeks, so long-term effects on fibrosis progression or liver-related mortality are not yet established. Diagnostic heterogeneity is a recurring theme across nearly all of the sources discussed here: studies define both low muscle mass and MASLD differently, which limits how precisely these findings can be compared or generalized. Finally, none of the major studies referenced here were conducted specifically in young Omani or Gulf adults, so how strongly this pattern applies to this site's specific population of interest remains an open, and researchable, question.

Connecting Back to Sarcopenic Obesity

The liver is not a separate concern from sarcopenic obesity; it looks increasingly like one of the organs most directly shaped by it. Weak or shrinking muscle and a fat-laden liver reinforce each other through shared hormonal and inflammatory signaling, and that loop appears to start well before the ages at which liver disease is traditionally screened for. The encouraging counterpoint is that the same resistance training already recommended for building and protecting muscle in sarcopenic obesity shows up in controlled trials as a way to reduce liver fat as well, suggesting that addressing the muscle side of this condition may help protect the liver too. This post is for general education and is not medical advice. Any concerns about liver health or muscle mass should be discussed with a qualified healthcare provider.

References

• Nutrition & Metabolism (2025) — Wang, Liu, Du, Qiu, Liu, Xu, and Zhang: Prevalence and Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Sarcopenic Obesity, a Systematic Review and Meta-Analysis
• Nature Reviews Endocrinology (2025) — Zheng et al.: Sarcopenia and MASLD, Novel Insights and the Future
• Sci / MDPI (2024) — Martins-Mendes et al.: How Sarcopenia, Muscle Mass, Strength, and Performance Relate to Non-Alcoholic Fatty Liver Disease, a Systematic Review
• Frontiers in Physiology (2025) — Dai et al.: Resistance Training for Metabolic Dysfunction-Associated Steatotic Liver Disease, a Systematic Review and Meta-Analysis
• Nutrients (2023) — Bouzakri et al.: Myokines, Crosstalk and Consequences on Liver Physiopathology